

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE UNITED STATES DEPARTMENT OF COMMI United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandris, Viginia 22313-1450 www.usptu.gov

APPLICATION NUMBER

FILING OR 371 (c) DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

10/656,093

09/05/2003

Andrew A. Young

256/152DIV

David R. Marsh Attn: IP Docketing Dept. **ARNOLD & PORTER** 555 12th Street, N.W. Washington, DC 20004-1206



CONFIRMATION NO. 8873 **FORMALITIES LETTER**

OC000000012005137

Date Mailed: 03/02/2004

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES**

Filing Date Granted

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

 The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Replies should be mailed to:

Mail Stop Missing Parts

Commissioner for Patents

P.O. Box 1450

Alexandria VA 22313-1450

Docketed Due Date

Initial

2004

A copy of this notice MUST be returned with the reply.

Customer Service Center
Initial Patent Examination Division (703) 308-1202
PART 1 - ATTORNEY/APPLICANT COPY

Serial No. 10/656,093

Patent Atty Docket No. 256/152DIV

Group Art Unit: Unknown

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Young et al.

Confirmation No.: 8873 Serial No: 10/656,093 Filed: September 5, 2003

For: Inotropic and Diuretic Effects of GLP-1 and GLP-1 Agonists

Examiner: Unknown

Response Under 37 C.F.R. 1.821 and 37 C.F.R. 1.825

Commissioner for Patents Mail Stop Sequence P.O. Box 1450 Alexandria, VA 22313-1450

In response to the Formalities Letter dated March 2, 2004, a copy of which is enclosed, Applicants submit herewith a substitute computer readable form of the sequence listing for the above referenced application as required by 37 C.F.R. 1.825(d). In accordance with 37 C.F.R. 1,821 (f), I hereby state that information recorded in computer readable form (CRF) is identical to the corrected paper sequence listing mailed on February 9, 2004 and includes no new matter.

Applicants believe no fee is due with this response. In the event any fee is deemed necessary, the Commissioner is hereby authorized to charge any such fee that may be required or to credit any overpayment of fees during the pendency of this application to Account No. 01-0535.

Respectfully submitted,

James E. Butler, Ph.D., Reg No. 40,931

Amylin Pharmaceuticals, Inc. 9360 Towne Centre Drive San Diego, CA 92121

(858) 458-8564

PR 127	MA Ender the Panetwork	gn (+) inside this box Reduction Act of 1995, no			ed for use through 10/31/2002. OMB 0651-0031 rk Office: U.S. DEPARTMENT OF COMMERCE imation unless it displays a valid OMB control number.
	Soung, et al Univ	oung, TRANSMITTAL		Application Number	10/656,093
CHAUEY				Filing Date	September 5, 2003
	FORM (to be used for all correspondence after initial filing)			First Named Inventor	Young et al.
				Group Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
	Total Number of Page	s in This Submission	4	Attorney Docket Number	256/152DIV
•	ENCLOSURES (check all that apply)				
	Fee Transmittal Form		Assignment Papers (for an Application)		After Allowance Communication to Group
	Fee Attached	Fee Attached		g(s)	Appeal Communication to Board of Appeals and Interferences
•	Amendment / Response After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement		Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Address Terminal Disclaimer Request for Refund CD, Number of CD(s)		Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
					Proprietary Information
					Status Letter
					Other Enclosure(s) (please identify below): Response to Formalities Letter Substitute CRF of Sequence Listing Disk Copy of Formalities Letter Return Post Card
	Certified Copy of Priority Document(s)		Rema	rks	
	Response to Missing Parts/ Incomplete Application				
•	Response to Missing Parts under 37 CFR 1.52 or 1.53				
۲	SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT				
	Firm <i>or</i> Individual name	Amylin Pharmaceuticals, Inc. James E. Butler, Ph.D., Reg. No		o. 40,931	
	Signature	gnature Janus & Bul			
•	Date April 9, 2004				
	CERTIFICATE OF MAILING				

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Typed or printed name

Amanda J. Halverson